Keyphrases
Israel
100%
COVID-19
67%
BNT162b2 Vaccine
47%
Neutralizing Antibodies
41%
BNT162b2
38%
Immunogenicity
32%
Healthcare Workers
32%
West Nile Virus
27%
Third Dose
25%
Receptor-binding Domain
24%
Humoral Response
22%
Travellers
22%
IgG Antibody
22%
Vaccine Dose
22%
Vaccination
20%
COVID-19 Vaccine
20%
Israeli
19%
Zika Virus
17%
Antibody Response
16%
Immune Response
15%
Seroprevalence
15%
Second Dose
14%
Dengue
12%
Omicron Variant
12%
Antibody Titer
11%
Enzyme-linked Immunosorbent Assay (ELISA)
11%
Zika Virus Infection
11%
Confidence Interval
11%
Adverse Events
10%
West Nile Virus Infection
10%
Quantitative PCR
10%
Seropositivity
10%
Immunoglobulin G Antibodies
10%
BNT162b2 COVID-19 Vaccine
9%
Liver Transplant Recipients
9%
Virus RNA
9%
COVID-19 Vaccination
9%
Breakthrough Infection
9%
Geometric Mean Titer
9%
Zika
8%
Prospective Cohort Study
8%
Two-dose
8%
Dengue Virus
8%
Human Infection
8%
Dengue Infection
8%
Signal Recognition Particle
8%
SARS-CoV-2 Infection
8%
Antireceptor
8%
Dengue Fever
8%
BA.1
7%
Immunology and Microbiology
Vaccine Efficacy
76%
Severe Acute Respiratory Syndrome Coronavirus 2
69%
COVID-19
59%
Vaccination Policy
44%
Neutralizing Antibody
37%
Immunoglobulin G Antibody
25%
Omicron Coronavirus Variant
23%
Receptor Binding
23%
Humoral Immunity
22%
West Nile Virus
22%
Transplant Procedure
19%
Antibody Titer
18%
Antibody Response
18%
Neutralization
17%
Immunogenicity
17%
Dengue Fever
17%
Monospecific Antibody
16%
Titer
15%
Spike
13%
Immune Response
12%
Phylogeny
11%
Viral Disease
10%
Seroprevalence
10%
RNA Interference
9%
Seropositivity
8%
Serology
8%
Trypanosoma Brucei
8%
Breakthrough Infection
8%
Wild Type
8%
Lineages
6%
Booster Dose
6%
Cross-Reactivity
6%
Enzyme-Linked Immunosorbent Assay
6%
Prevalence
6%
T Cell
6%
Immunoglobulin G
5%
Flavivirus
5%
RNA Vaccine
5%